摘要
目的：评价厄洛替尼联合卡培他滨二线治疗胰腺癌的疗效、临床获益和毒性反应。方法：回顾分析13例胰腺癌患者临床资料,所有患者均接受至少两周期化疗,卡培他滨1250mg/（m2·d）,口服,第1~14天。厄洛替尼片150mg,口服,1次/d,每3周方案。结果：近期客观有效率为38%,中位TTP（2.6±1.2）个月,6个月、12个月生存率分别为46%（6/13）、7%（1/13）,中位生存期为6.1个月,CA19-9显著降低,体力状态改善率54%。主要不良反应是胃肠道反应、皮疹、手足综合症、中性粒细胞减少。无腹泻、外周静脉炎、肝肾功能损害等,无化疗相关死亡。结论：卡培他滨联合厄洛替尼二线治疗胰腺癌患者有效,不良反应较少,可提高患者的生活质量。
objective：To evaluate capecitabine combined with erlotinib for second-line treatment of pancreatic carcinoma,clinical benefit response and toxicity.Methods：Retrospectived analysis of clinical data in 13 patients,all patients underwent at least two cycles of chemotherapy,capecitabine 1250 mg/（m2·d）,oral,the 1~14 days,erlotinib 150 mg,oral,1 time/d,3 weekly scheme.Results：The short-term objective efficiency was 38%,in TTP （2.6±1.2） months,6,12 month survival rates were 46% （6/13）,7%（1/13）,the median survival time was 6.1 months,CA19-9 decreased,physical state of improvement of 54%.Major adverse effects were gastrointestinal reaction,skin rash, hand-foot syndrome, neutropenia.Without diarrhea, peripheral phlebitis,liver and kidney dysfunction, without chemotherapy related death.Conclusion：The capecitabine combined with erlotinib in second-line treatment of patients with pancreatic cancer effectively,less adverse reactions,which can improve the patients’ quality of life.
出处
《中国医学创新》
CAS
2012年第10期23-24,共2页
Medical Innovation of China
关键词
卡培他滨
厄洛替尼
胰腺癌
二线治疗
Capecitabine
Erlotinib
Pancreatic cancer
Second-line treatment
